Biofrontera Inc. BFRI PHARMA
Company Overview
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Why Investors Should Care
Revenue has grown at a 17.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $41.70M (+11.7% YoY); net profit $-10.54M.
- Trailing 12 Months Year-on-year growth — revenue +32.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.21% |
| 1 Year: | 32.90% |
Stock Price Performance
| 1 Year: | +64.21% |
| 6 Months: | +89.32% |
| 3 Months: | +67.74% |
| 1 Month: | +22.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BFRI Biofrontera Inc. PHARMA | 1.56 | -3.63 | $23.17M | 0.00% | -68.08% | - | 17.21% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.25M | 4.74M | 5.86M | 4.33M | 9.75M | 4.46M | 4.32M | 8.73M | 5.85M | 8.90M | 7.91M | 7.84M | 9.01M | 8.59M | 9.03M | 6.99M | 10.08M |
| Operating Income | -2.34M | -3.53M | -3.69M | -16.11M | -3.11M | -6.21M | -3.64M | -5.49M | -8.70M | -4.62M | -5.47M | -5.07M | -4.96M | -4.55M | -5.08M | -6.28M | -4.32M |
| Net Income | -2.98M | -3.53M | -3.66M | -16.01M | 5.56M | -850.00K | -2.57M | -7.48M | -9.84M | -6.34M | -10.44M | -257.00K | -5.67M | -4.20M | -5.32M | -6.65M | -4.75M |
| Diluted EPS | - | -0.44 | -0.46 | -2.00 | 0.32 | -0.90 | -2.26 | -5.60 | -7.23 | -4.64 | -2.88 | -0.05 | -0.98 | -0.47 | -0.57 | -0.62 | -0.41 |
| R&D Expense | - | - | - | - | - | - | - | - | 11.00K | 33.00K | 17.00K | 621.00K | 669.00K | 1.21M | 870.00K | 854.00K | 900.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 18.85M | 24.10M | 28.67M | 34.07M | 37.32M | 41.70M |
| Operating Income | -9.61M | -25.20M | -18.58M | -22.68M | -17.21M | -11.35M |
| Net Income | -10.99M | -37.71M | -640.00K | -20.13M | -17.76M | -10.54M |
| Diluted EPS | - | - | -0.61 | -13.02 | -3.22 | -1.04 |
| R&D Expense | - | - | - | 77.00K | 2.09M | 3.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 24.14M | 53.22M | 50.88M | 27.93M | 22.10M | 28.56M |
| Total Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M | 10.48M |
| Cash & Equivalents | - | 8.08M | 24.55M | 17.21M | 1.34M | 5.91M | 6.39M |
| Total Liabilities | - | 18.31M | 41.88M | 27.01M | 23.14M | 17.67M | 18.08M |
| Current Liabilities | - | 4.42M | 13.84M | 20.89M | 18.09M | 12.02M | 11.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.37M | -26.71M | -16.20M | -24.89M | -10.27M | -13.36M |
| Investing Cash Flow | - | -11.00K | -5.16M | 619.00K | -3.00K | 3.00M |
| Financing Cash Flow | 13.19M | 43.19M | 14.02M | 8.41M | 14.84M | 10.85M |
| Capital Expenditure | - | - | -38.00K | -5.00K | -10.00K | -2.00K |
| Free Cash Flow | - | - | -16.24M | -24.90M | -10.28M | -13.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -51.0% | -104.6% | -64.8% | -66.6% | -46.1% | -27.2% |
| Net Margin % | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |
| ROE % | -188.5% | -332.6% | -2.7% | -420.0% | -400.6% | -100.5% |
| ROCE % | -48.7% | -64.0% | -62.0% | -230.4% | -170.7% | -68.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 8.59% | 1.28M | $1.68M |
| 2 | AIGH Capital Management LLC | 4.98% | 739.91K | $976.68K |
| 3 | Renaissance Technologies, LLC | 1.06% | 157.50K | $207.91K |
| 4 | Citadel Advisors Llc | 0.71% | 104.94K | $138.52K |
| 5 | Jane Street Group, LLC | 0.63% | 93.00K | $122.76K |
| 6 | Geode Capital Management, LLC | 0.52% | 76.69K | $101.23K |
| 7 | Vanguard Capital Management LLC | 0.48% | 71.38K | $94.22K |
| 8 | Vanguard Fiduciary Trust Co | 0.42% | 61.70K | $81.44K |
| 9 | Xtx Topco Ltd | 0.35% | 51.89K | $68.50K |
| 10 | HRT Financial LP | 0.29% | 43.35K | $57.22K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BFRI
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNVHFvZWhLd1hBZTJDTFk1b0FVS2M2THZsR0xNcndTVENNcWpYc2NhbXdwMHlGYl9pZzAxbkhIVzhveXhxUndJbng1b1NhaXJuNHpRRE1uYmJabTZMMFFmLWJwMkQ3Sk40RVFmRkJZWmgybGUxcnNrYkcxdFV5Z24yRlRpQkkwNFI0SDRic0…
BIOFRONTERA ($BFRI) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPZ3R5N1dMZFM4TkgwSnQ5QTFIak8zcy0xb3otNDdVZXUzOUlPb0luZ2ZFQkxrUjZQLXMxRHRwTDluVHFDdVhtVVlSSG8yRDRFZ19vY3VDb2hwZGF2S3VFR2pzYmVkTWJKQmVQMWYwaHVvaTFaV1QxZlRhSG5SaUxITzJjZ3VWZU11cnRvZg…
Biofrontera schedules Aug. 13 webcast for business update - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNN3RhZFlNaEdMOGczMHFMX2RXc1pfMzNxeU52WnlPVUFHNnJCMjRQZzVIaTlISnlnUklydFFQT3VzU21GdFllTUZoRjV4LVB1YnBVQ1BhSGZackJpVW43ZGkyZTVGWDI2bW5wazhjOWVRc2dseEJ2M2dqdS1yYTNlMHdzSGYzRGQ1akVacD…
BFRI - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1TV1NRcU94dUxLQzM2bTlJMjB2dWJ0TnRSc2E2eEt5UHdmTWhLaVVOMjRTUlgtVDJJTEluRU00bExOY2lZdmc?oc=5" target="_blank">BFRI</a> <font color="#6f6f6f">Finviz</font>…
Biofrontera Inc.'s (NASDAQ:BFRI) Path To Profitability - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPX0hMMUNmQ2NITDQyVHhOeHZNRWJ3czZmbkxfSGZhQUR2UXJvWXB0NjR6aDlvVTgxSFR3bVhpNTlzeDdhUlllSG90eGZBM1ViRExHQ2p1X3A5SHN2Zi1sQU9vOEEtSlJncnd1QmlIcGI3RExsN1lkQ011Qk9jT2xkSTZHWEtyN1U2TEs5Qn…
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOSXdpZV94UXMtWFp1alp5WVA0eXdEMklsdHFZdWNiNGVLUzJIZy1XNE9YS2ZHUG1obFZxd2IxaGZfQWEwXy1NSWlPREZmeXdYQlF4R0hGT3I1SlFacjhmdEU5c3k2dnc2S1ZBazhSc3F5ZHFkSzU0dlBRVHU4NENHWGlMb2dZTDhoR2tZaj…
BFRI — Frequently Asked Questions
What is the current share price of Biofrontera Inc. (BFRI)?
As of 2026-09-19 21:16 PDT, Biofrontera Inc. (BFRI) trades at $1.56 on NasdaqCM. Its 52-week range is $0.57 to $1.61.
What is the market capitalisation of BFRI?
Biofrontera Inc. (BFRI) has a market capitalisation of $23.17M on NasdaqCM.
What is the P/E ratio of BFRI?
BFRI trades at a trailing price-to-earnings (P/E) ratio of -3.63. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.68.
Is BFRI a good stock to buy?
This page provides a data-driven analysis of Biofrontera Inc. (BFRI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.